Novel, isoform-selective, cholecystokinin A receptor antagonist inhibits colon and pancreatic cancers in preclinical models through novel mechanism of action

被引:6
作者
Ponnusamy, Suriyan [1 ]
Lattmann, Eric [2 ]
Lattmann, Pornthip [3 ]
Thiyagarajan, Thirumagal [1 ]
Padinjarethalakal, Balaram N. [3 ]
Narayanan, Ramesh [1 ,4 ]
机构
[1] Univ Tennessee, Ctr Hlth Sci, Dept Med, 19 South Manassas,Room 120, Memphis, TN 38163 USA
[2] Aston Univ, Sch Life & Hlth Sci, Div Pharm, Birmingham B4 7ET, W Midlands, England
[3] PNB Vesper Life Sci, Cochin, Kerala, India
[4] West Canc Ctr, Memphis, TN USA
关键词
cholecystokinin; CCK-A; CCK-B; gastrin; colon cancer; pancreatic cancer; kinases; G-protein coupled receptor; CELL-PROLIFERATION; GROWTH-FACTOR; CCK-A; GASTRIN; CARCINOGENESIS; ADENOCARCINOMA; COMBINATION; EXPRESSION; SYNERGISM; THERAPY;
D O I
10.3892/or.2016.4588
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Colon and pancreatic cancers contribute to 90,000 deaths each year in the USA. These cancers lack targeted therapeutics due to heterogeneity of the disease and multiple causative factors. One important factor that contributes to increased colon and pancreatic cancer risk is gastrin. Gastrin mediates its actions through two G-protein coupled receptors (GPCRs): cholecystokinin receptor A (CCK-A) and CCK-B/gastrin receptor. Previous studies have indicated that colon cancer predominantly expresses CCK-A and responds to CCK-A isoform antagonists. However, many CCK-A antagonists have failed in the clinic due to poor pharmacokinetic properties or lack of efficacy. In the present study, we synthesized a library of CCK-A isoform-selective antagonists and tested them in various colon and pancreatic cancer preclinical models. The lead CCK-A isoform, selective antagonist PNB-028, bound to CCK-A at 12 nM with a 60-fold selectivity towards CCK-A over CCK-B. Furthermore, it inhibited the proliferation of CCK-A-expressing colon and pancreatic cancer cells without affecting the proliferation of non-cancerous cells. PNB-028 was also extremely effective in inhibiting the growth of MAC-16 and LoVo colon cancer and MIA PaCa pancreatic cancer xenografts in immune-compromised mice. Genome-wide microarray and kinase-array studies indicate that PNB-028 inhibited oncogenic kinases and angiogenic factors to inhibit the growth of colon cancer xenografts. Safety pharmacology and toxicology studies have indicated that PNB-028 is extremely safe and has a wide safety margin. These studies suggest that targeting CCK-A selectively renders promise to treat colon and pancreatic cancers and that PNB-028 could become the next-generation treatment option.
引用
收藏
页码:2097 / 2106
页数:10
相关论文
共 38 条
  • [1] Circulating miRNAs miR-34a and miR-150 associated with colorectal cancer progression
    Aherne, Sinead T.
    Madden, Stephen F.
    Hughes, David J.
    Pardini, Barbara
    Naccarati, Alessio
    Levy, Miroslav
    Vodicka, Pavel
    Neary, Paul
    Dowling, Paul
    Clynes, Martin
    [J]. BMC CANCER, 2015, 15
  • [2] Gastrins, cholecystokinins and gastrointestinal cancer
    Aly, A
    Shulkes, A
    Baldwin, GS
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2004, 1704 (01): : 1 - 10
  • [3] [Anonymous], CANCER S4
  • [4] BIBBY MC, 1987, JNCI-J NATL CANCER I, V78, P539
  • [5] AN ONCOGENE ISOLATED BY TRANSFECTION OF KAPOSIS-SARCOMA DNA ENCODES A GROWTH-FACTOR THAT IS A MEMBER OF THE FGF FAMILY
    BOVI, PD
    CURATOLA, AM
    KERN, FG
    GRECO, A
    ITTMANN, M
    BASILICO, C
    [J]. CELL, 1987, 50 (05) : 729 - 737
  • [6] Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2
    Cao, RH
    Bråkenhielm, E
    Pawliuk, R
    Wariaro, D
    Post, MJ
    Wahlberg, E
    Leboulch, P
    Cao, YH
    [J]. NATURE MEDICINE, 2003, 9 (05) : 604 - 613
  • [7] CYCLIC CHOLECYSTOKININ ANALOGS WITH HIGH SELECTIVITY FOR CENTRAL RECEPTORS
    CHARPENTIER, B
    PELAPRAT, D
    DURIEUX, C
    DOR, A
    REIBAUD, M
    BLANCHARD, JC
    ROQUES, BP
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (06) : 1968 - 1972
  • [8] Clerc P, 1997, INT J CANCER, V72, P931, DOI 10.1002/(SICI)1097-0215(19970917)72:6<931::AID-IJC2>3.0.CO
  • [9] 2-Q
  • [10] Long-term survival, prevalence, and cure of cancer: a population-based estimation for 818 902 Italian patients and 26 cancer types
    Dal Maso, L.
    Guzzinati, S.
    Buzzoni, C.
    Capocaccia, R.
    Serraino, D.
    Caldarella, A.
    Dei Tos, A. P.
    Falcini, F.
    Autelitano, M.
    Masanotti, G.
    Ferretti, S.
    Tisano, F.
    Tirelli, U.
    Crocetti, E.
    De Angelis, R.
    [J]. ANNALS OF ONCOLOGY, 2014, 25 (11) : 2251 - 2260